Cessatech A/S

Quick facts

Phase 2 pipeline

• CT001 · Neurology
  CT001 is a gene editing therapy that uses CRISPR-Cas9 to edit the SMN1 gene.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cessatech A/S portfolio CI brief
• Cessatech A/S pipeline updates RSS